Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.
IPO Year: 2020
Exchange: NASDAQ
Website: abcam.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/20/2023 | $23.00 → $22.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 6/16/2023 | $25.00 | Neutral → Buy | BofA Securities |
| 12/14/2022 | $15.00 | Hold | Deutsche Bank |
WASHINGTON, Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023. As a result, Abcam has become an indirect wholly owned subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has been suspended. The consideration due to former Abcam shareholders will be settled pursuant to the terms of the Scheme and the consideration due to former Abcam ADS
Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘). Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme. Closing of the T
Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), today announced that all Identified Clearances required in connection with the Transaction have been obtained from the relevant Governmental Authorities. The Transaction remains subject to the sanction of the Scheme by the High Court of Justice of England and Wales and the satisfaction or waiver (if applicable) of certain other customary closing conditions as set out in Par
Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher'), today announced that its shareholders have approved the proposal for Danaher to acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction'). "On behalf of Abcam's Board of Directors, I would like to thank all our shareholders for their support for the Transaction," said Peter Allen, Chairman of the Board. "With this approval, we are focused on moving swiftly toward transaction close and
Statement from Dr. Jonathan Milner on the suspension of the "Vote AGAINST" campaign CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.16% of the Company, today issued the following statement in relation to the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher"). "After extensive feedback from the majority of Abcam's shareholders, I have today decided to suspend my "Vote AGAINST" campaign. It has become clear that a significant majority intend to support Danaher's acquisition of Abcam and I respect this decision and will not stan
Both Leading Proxy Advisors ISS and Glass Lewis Acknowledge the Thorough Process Undertaken by the Abcam Board in Reaching an Agreement that Provides a Compelling Premium and Certainty of Value to Abcam Shareholders Abcam plc (NASDAQ:ABCM) (‘Abcam,' the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, announced that leading independent proxy advisor, Glass Lewis, recommended that Abcam shareholders vote "FOR" Danaher Corporation's ("Danaher" or "DHR") proposed acquisition of Abcam (the "Transaction") ahead of its shareholder meetings on November 6, 2023. Alan Hirzel, Chief Executive Officer of Abcam, said: "Following the publication of Glass Lewis
Jonathan Milner Issues Statement Responding to the Glass Lewis Report Welcomes the Glass Lewis report's observations on the disproportionate rewards for Abcam's Executive Directors and on the identified issues with peer group valuation strategies Urges Shareholders to continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher CAMBRIDGE, England, 23 October 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.16% of the Company, has today issued the following statement in response to a 21 October 2023 report from Glass Lewis. Jonathan Milner urges shareholders to continue to vote AGAI
ISS Acknowledges the Thorough Process Undertaken by the Abcam Board in Reaching an Agreement that Provides a Premium and Certainty of Value to Abcam Shareholders Abcam plc (NASDAQ:ABCM) (‘Abcam,' the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, today announced that leading independent proxy advisor Institutional Shareholder Services (‘ISS'), recommended that Abcam shareholders vote "FOR" Danaher Corporation's (‘Danaher' or ‘DHR') proposed acquisition of Abcam (the ‘Transaction') ahead of its shareholder meetings on November 6, 2023. Alan Hirzel, Chief Executive Officer of Abcam, said: "We are pleased that ISS supports our board's unanimous rec
Jonathan Milner Issues Statement Responding to ISS Report Urges shareholders to disregard the ISS report and continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher CAMBRIDGE, England, 16 October 2023 – Jonathan Milner, the founder and one of the largest shareholders in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.16% of the Company, has today issued the following statement in response to a 16 October 2023 report from Institutional Shareholder Service ("ISS"). Jonathan Milner urges shareholders to continue to vote AGAINST the current proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher").Commenting on the
Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company CAMBRIDGE, England, 16 October 2023 – Dr. Jonathan Milner, the founder and one of the largestshareholders in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.16%, today issued a presentation covering the reasons for Abcam shareholders to vote against the $24 per share bid from Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher"). These include: Data showing that the forward multiple implied by the $24 bid price is below Abcam's long-term trading multipleThe anticipation of a transformational year ahead with increased EB
Jonathan Milner issues Open Letter to shareholders of Abcam plc Highlights Company's loss of focus on governance, execution and cost control leading to value destruction and a share price materially below where it should be Outlines Milner's plan to restore shareholder trust and value and make Abcam the world leading antibody company once again CAMBRIDGE, England, 12 June 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.3% of the Company, has today issued an open letter to the Company's shareholders calling for the removal of Peter Allen, Michael S. Baldock and Sally W. Crawford as Directors of th
Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary General Meeting of Abcam Shareholders Delivers Open Letter to Abcam shareholders Follows sustained period of operational underperformance since the start of 2020 and a track record of value destruction under the current Board and leadership team Critical for shareholders to have a platform to exert their right to restore focus for Abcam on governance, execution, and cost control to elevate it to the valuation it rightly deserves CAMBRIDGE, England, 17 May 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.3% of the Company, a
CAMBRIDGE, England, June 27, 2022 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (NASDAQ:ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations. Tommy, who will be based in our Waltham, MA office, has over 20 years' experience in the life sciences sector, largely focused in the area of research tools. He joins Abcam from Avantor, where he was Vice President, Investor Relations for several years. Prior to this he was Vice President of Investor Relations, and then Chief Financial Officer of Global Services at Perkin Elmer. Before joining Perkin Elmer, Tommy spent eight
BRISBANE, Australia, March 18, 2021 /PRNewswire/ -- Microba Life Sciences has appointed international executive, Mark Capone, as a Non-Executive Director of the Board, bringing with him more than 35 years of experience in the life sciences sector. Mr Capone spent 17 years with Myriad Genetics, most recently as President and CEO, where he transformed a pioneering start-up into one of the largest precision medicine companies in the world. Mr Capone led Myriad to total annual revenues of more than $800 million and steered the development and launch of more than a dozen reimbursed molecular diagnostics. Prior to Myriad, Mr Capone had a career with Eli Lilly and Company also spanning 17 years, wo
CAMBRIDGE, United Kingdom, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, is delighted to announce the appointments of Bessie Lee and Mark Capone as non-executive Directors with immediate effect. Both Bessie and Mark bring extensive and complementary executive and non-executive experience to the Board of Abcam. Based in China, Bessie Lee is the Chief Executive Officer of Withinlink, a China-based venture capital firm and start-up incubator focused on marketing technology, which she founded in 2015. Prior to founding Withinlink, Bessie spent almost three decades at WPP plc, holding Chief Executi
RBC Capital Mkts downgraded Abcam from Outperform to Sector Perform and set a new price target of $22.00 from $23.00 previously
BofA Securities upgraded Abcam from Neutral to Buy and set a new price target of $25.00
Deutsche Bank initiated coverage of Abcam with a rating of Hold and set a new price target of $15.00
SVB Leerink reiterated coverage of Abcam with a rating of Outperform and set a new price target of $25.00 from $26.00 previously
Berenberg Bank resumed coverage of Abcam with a rating of Hold
JPMorgan Chase & Co. resumed coverage of Abcam with a rating of Neutral
Royal Bank of Canada resumed coverage of Abcam with a rating of Outperform
SVB Leerink reiterated coverage of Abcam with a rating of Outperform and set a new price target of $25.00 from $26.00 previously
SVB Leerink reiterated coverage of Abcam with a rating of Outperform and set a new price target of $26.00 from $22.00 previously
Jonathan Milner issues Open Letter to shareholders of Abcam plc Urges shareholders to Vote AGAINST the proposed acquisition of Abcam by Danaher Corporation CAMBRIDGE, England, 28 September 2023 – Dr. Jonathan Milner, the founder and one of the largestinvestors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.15%, todayissued an open letter to the Company's shareholders announcing his "Vote AGAINST" campaign and providing them with the opportunity to send a clear message to the Board that they are dissatisfied with the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher") and Abcam's governance, execution and cost control.
Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board CAMBRIDGE, England, 14 September 2023 – Dr. Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.14%, today announces his decision to vote against the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher"). In addition to this, he will formally request the Abcam Board of Directors to convene a General Meeting ("EGM") with the purpose of replacing the Company's Board, including the current CEO, CFO and Chairman. Jonathan Milner's decision to oppose the acquisition is informed by e
Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) (‘Danaher') will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction'). The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors. Founded in 1998 and headquartered in Cambridge, UK, Abcam offers the scientific community highly validated antibodies, reagents, biomarkers and assays to address targets in biological pat
15% Reported Revenue Growth & 8% Constant Exchange Rate Revenue Growth: Demand for Abcam In-house Products Continues CAMBRIDGE, England and WALTHAM, Mass. , March 20, 2023 /PRNewswire/ -- Abcam plc (NASDAQ:ABCM) ('Abcam', the 'Group' or the 'Company'), a global leader in the supply of life science research tools, today announces its results for the year ended 31 December 2022 (the 'period'). SUMMARY PERFORMANCE Year-End 31 December 2022 £m 2021 £m Revenue 361.7 315.4 Gross profit margin, % Adjusted gross profit margin, % 74.8% 75.5% 71.2% 72.2% Operating profit margin, % Adjusted operating profit margin, % Diluted (loss) / earnings per share ('
CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc ((AIM LSE: ABC, NASDAQ:ABCM) ("Abcam", "the Company" or "the Group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. ("BioVision"), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. ("NKY"), for $340 million (the "Acquisition"). Transaction highlights BioVision is a fast-growing innovator and distributor of life science research tools to biopharma, diagnostic and academic customers, with strength in biochemical and cell-based assay kitsBrings one of Abcam's large third-party suppliers in-houseAccelerates
15-12G - Abcam plc (0001492074) (Filer)
S-8 POS - Abcam plc (0001492074) (Filer)
S-8 POS - Abcam plc (0001492074) (Filer)
S-8 POS - Abcam plc (0001492074) (Filer)
POSASR - Abcam plc (0001492074) (Filer)
25-NSE - Abcam plc (0001492074) (Subject)
6-K - Abcam plc (0001492074) (Filer)
6-K - Abcam plc (0001492074) (Filer)
6-K - Abcam plc (0001492074) (Filer)
6-K - Abcam plc (0001492074) (Filer)
SC 13G/A - Abcam plc (0001492074) (Subject)
SC 13G/A - Abcam plc (0001492074) (Subject)
SC 13D/A - Abcam plc (0001492074) (Subject)
SC 13D/A - Abcam plc (0001492074) (Subject)
SC 13D/A - Abcam plc (0001492074) (Subject)
SC 13D/A - Abcam plc (0001492074) (Subject)
SC 13D/A - Abcam plc (0001492074) (Subject)
SC 13D/A - Abcam plc (0001492074) (Subject)
SC 13D - Abcam plc (0001492074) (Subject)
SC 13D/A - Abcam plc (0001492074) (Subject)